AU641407B2 - Octreotide-pamoate - Google Patents

Octreotide-pamoate Download PDF

Info

Publication number
AU641407B2
AU641407B2 AU58746/90A AU5874690A AU641407B2 AU 641407 B2 AU641407 B2 AU 641407B2 AU 58746/90 A AU58746/90 A AU 58746/90A AU 5874690 A AU5874690 A AU 5874690A AU 641407 B2 AU641407 B2 AU 641407B2
Authority
AU
Australia
Prior art keywords
octreotide
pamoate
preparation
acid
spe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU58746/90A
Other languages
English (en)
Other versions
AU5874690A (en
Inventor
David Bodmer
Jones Wing Fong
Thomas Kissel
Hawkins Valliant Maulding
Oskar Nagele
Jane Edna Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU5874690A publication Critical patent/AU5874690A/en
Application granted granted Critical
Publication of AU641407B2 publication Critical patent/AU641407B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request to Amend Deed and Register Assignors: SANDOZ LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU58746/90A 1989-07-07 1990-07-05 Octreotide-pamoate Expired AU641407B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US377023 1989-07-07
US41134789A 1989-09-22 1989-09-22
US411347 1989-09-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU41985/93A Division AU662825B2 (en) 1989-07-07 1993-07-15 Process for the production of microparticles
AU41986/93A Division AU663388B2 (en) 1989-07-07 1993-07-15 Sustained release formulations

Publications (2)

Publication Number Publication Date
AU5874690A AU5874690A (en) 1991-01-10
AU641407B2 true AU641407B2 (en) 1993-09-23

Family

ID=27007654

Family Applications (2)

Application Number Title Priority Date Filing Date
AU58746/90A Expired AU641407B2 (en) 1989-07-07 1990-07-05 Octreotide-pamoate
AU23321/95A Expired AU687553B2 (en) 1989-07-07 1995-06-29 Process for the production of microparticles

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU23321/95A Expired AU687553B2 (en) 1989-07-07 1995-06-29 Process for the production of microparticles

Country Status (27)

Country Link
JP (5) JPH0832624B2 (es)
KR (2) KR100303681B1 (es)
AT (1) AT406225B (es)
AU (2) AU641407B2 (es)
BE (1) BE1004486A3 (es)
CA (1) CA2020477C (es)
CH (1) CH685230A5 (es)
CY (1) CY1965A (es)
DE (2) DE4021517B4 (es)
DK (1) DK175849B1 (es)
FI (3) FI108611B (es)
FR (1) FR2649319A1 (es)
GB (2) GB2234896B (es)
GR (1) GR1001121B (es)
HK (2) HK97695A (es)
HU (2) HU221294B1 (es)
IE (2) IE64411B1 (es)
IL (3) IL131880A (es)
IT (1) IT1241460B (es)
LU (1) LU87764A1 (es)
MY (1) MY106722A (es)
NL (1) NL195027C (es)
NO (2) NO302928B1 (es)
NZ (1) NZ234384A (es)
PT (1) PT94628B (es)
SE (1) SE512992C2 (es)
SG (1) SG26416G (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
DE4218510A1 (de) * 1992-06-02 1993-12-09 Pharmatech Gmbh Verfahren zur Herstellung biologisch abbaubarer Polyester
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
EP0626170A3 (en) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacoligically active compounds in controlled release compositions.
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
JP3645906B2 (ja) 1993-11-19 2005-05-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ マイクロカプセル封入された３−ピペリジニル−置換１，２−ベンズイソオキサゾール類及び１，２−ベンズイソチアゾール類
JP2000500744A (ja) 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
DE60130917T2 (de) 2000-12-21 2008-07-17 Alrise Biosystems Gmbh Induziertes phasenübergangsverfahren zur herstellung von hydrophile wirkstoffe enthaltenden mikropartikeln
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
JP2008518881A (ja) * 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
KR20060129394A (ko) * 2004-02-26 2006-12-15 독립행정법인 과학기술진흥기구 단백성 약물의 주사용 서방성 미립자 제제 및 이의제조방법
DE102004053373A1 (de) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Erfindung betreffend anisometrische Partikel in Form von Nano-/Meso-Fasern -Röhren, -Kabeln -Bändern und deren gekrümmte oder verzweigte Abwandlungen
KR100741867B1 (ko) * 2005-07-05 2007-07-24 전북대학교산학협력단 수중유적 및 용매 증발법을 이용한 이중층 미립구의제조방법
KR101458728B1 (ko) * 2005-12-22 2014-11-05 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
KR101921800B1 (ko) 2008-01-30 2018-11-23 노파르티스 아게 옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2813302A1 (en) * 2010-09-30 2012-04-05 Evonik Corporation Emulsion method for preparing low residual solvent microparticles
AU2011308893B2 (en) * 2010-09-30 2015-04-23 Evonik Corporation Method for removing residual organic solvent from microparticles
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
KR102464650B1 (ko) 2016-05-03 2022-11-10 엘에스일렉트릭(주) 배선용 차단기의 한류장치
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH649217A5 (de) * 1977-08-25 1985-05-15 Sandoz Ag Bromocriptin enthaltende mikrokapseln.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
CY1327A (en) * 1979-11-27 1986-06-27 Sandoz Ag Novel polypeptides,processes for their production,pharmaceutical compositions comprising said polypeptides and their use
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (ja) * 1986-03-06 1996-10-02 日本原子力研究所 ポリラクトンからなる徐放性薬物複合体の製造方法
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (es) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル

Also Published As

Publication number Publication date
HUT54037A (en) 1991-01-28
HU211602A9 (en) 1995-12-28
FI903429A0 (fi) 1990-07-06
IL94983A (en) 1999-08-17
JPH07309897A (ja) 1995-11-28
IE64411B1 (en) 1995-08-09
FI109334B (fi) 2002-07-15
NL195027B (nl) 2003-08-01
JPH07285853A (ja) 1995-10-31
SE9002364D0 (sv) 1990-07-05
CA2020477C (en) 2000-11-21
DE4042752B4 (de) 2009-05-07
HU903974D0 (en) 1990-11-28
FI20000060A (fi) 2000-01-12
DK162590D0 (da) 1990-07-05
SE512992C2 (sv) 2000-06-12
IT9048113A0 (it) 1990-07-05
DE4021517A1 (de) 1991-01-17
JPH08198771A (ja) 1996-08-06
ATA144090A (de) 1999-08-15
FR2649319A1 (fr) 1991-01-11
AU687553B2 (en) 1998-02-26
SG26416G (en) 1995-09-01
DK175849B1 (da) 2005-03-29
IE902435A1 (en) 1991-02-13
PT94628A (pt) 1991-03-20
CA2020477A1 (en) 1991-01-08
AU2332195A (en) 1995-09-07
NL9001537A (nl) 1991-02-01
NO302928B1 (no) 1998-05-11
GR1001121B (el) 1993-04-28
IT1241460B (it) 1994-01-17
JPH0368511A (ja) 1991-03-25
HU221294B1 (en) 2002-09-28
KR910002430A (ko) 1991-02-25
SE9002364L (sv) 1991-01-08
GB9306204D0 (en) 1993-05-19
GB2265311B (en) 1994-02-09
MY106722A (en) 1995-07-31
IL131880A (en) 2001-12-23
NO983923D0 (no) 1998-08-26
NO320444B1 (no) 2005-12-05
NO983923L (no) 1991-01-08
KR100303681B1 (ko) 2002-05-16
NZ234384A (en) 1994-05-26
AT406225B (de) 2000-03-27
JP2931773B2 (ja) 1999-08-09
FI108611B (fi) 2002-02-28
GB2265311A (en) 1993-09-29
GB2234896A (en) 1991-02-20
DK162590A (da) 1991-01-08
GB9014704D0 (en) 1990-08-22
NL195027C (nl) 2003-12-02
HK197496A (en) 1996-11-08
FR2649319B1 (es) 1994-12-09
GR900100513A (en) 1991-12-10
IE64216B1 (en) 1995-07-26
FI109543B (fi) 2002-08-30
GB2234896B (en) 1994-01-19
BE1004486A3 (fr) 1992-12-01
CH685230A5 (de) 1995-05-15
NO903001L (no) 1991-01-08
JPH0832624B2 (ja) 1996-03-29
IT9048113A1 (it) 1992-01-05
KR100442931B1 (ko) 2004-08-02
CY1965A (en) 1997-07-04
JP2001233897A (ja) 2001-08-28
IL94983A0 (en) 1991-06-10
PT94628B (pt) 1997-06-30
NO903001D0 (no) 1990-07-05
FI20000059A (fi) 2000-01-12
IL131881A (en) 2001-12-23
AU5874690A (en) 1991-01-10
LU87764A1 (fr) 1992-03-11
DE4021517B4 (de) 2009-04-09
HK97695A (en) 1995-06-23

Similar Documents

Publication Publication Date Title
AU641407B2 (en) Octreotide-pamoate
Iwanowicz et al. Preparation of N, N'-bis-tert-Butoxycarbonylthiourea
Carpino et al. tert-Butyloxycarbonyl and benzyloxycarbonyl amino acid fluorides. New, stable rapid-acting acylating agents for peptide synthesis
CA2121351C (en) The resolution of 5-methyltetrahydrofolic acid
HU185576B (en) Process for producing n-acylized l-proline derivatives
EP0916646A3 (en) Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
CA2360303A1 (en) Process for the preparation of pure citalopram
US11802103B2 (en) Process of making calcium alpha-ketoglutarate
US6794537B1 (en) Manufacturing processes for Se-methyl-L-selenocysteine
TW200510299A (en) Organic compounds
HU182707B (en) Process for isolating the salts of p-hydroxy-mandolic acid
AR038340A1 (es) Procedimiento para la preparacion de perindopril de alta pureza e intermediarios utiles en la sintesis
JPH03193799A (ja) ３―（ｌ―ピログルタミル）―ｌ―チアゾリジン―４―カルボン酸およびその誘導体の製造方法
DE69833951T2 (de) Verfahren zur herstellung von substituierten alkylaminen oder salzen davon
CA2109433C (en) Substituted benzhydrylamines as handles for solid phase peptide synthesis
JP2005306874A (ja) パントプラゾールナトリウム塩の多形体およびその製造方法
JP4279065B2 (ja) 亜鉛蛍光プローブ
EP0331073B1 (en) Benzhydrylamine derivatives
IL135323A (en) Process for the synthesis of -4 [-2 amino-6-chloro-9H-purine-9yl] -2-cyclopentane-1-methanol
AT394854B (de) Verfahren zur herstellung von n-l-alpha-aspartyl-l-phenylalanin(nieder)alkylestern
SU1246895A3 (ru) Способ получени производных /1,2,4/ триазол/4,3-а/хиноксалин-4-амина или их солей
EP0839801A3 (en) Production of benzophenone derivatives
KR950001041B1 (ko) 이환식 방향족 설포닐 클로라이드의 합성방법
JPS55104286A (en) Preparation of thienoimidazoline compound
AU714155B2 (en) Process for synthesizing carbapenem side chain intermediates